Bimekizumab Efficacy and Safety in Japanese Patients with Plaque Psoriasis in BE VIVID: A Phase 3, Ustekinumab and Placebo-Controlled Study-Reference-Cited by-同舟云学术

Bimekizumab Efficacy and Safety in Japanese Patients with Plaque Psoriasis in BE VIVID: A Phase 3, Ustekinumab and Placebo-Controlled Study

Published:2023-01-17 Issue:3 Volume:13 Page:751-768
ISSN:2193-8210
Container-title:Dermatology and Therapy
language:en
Short-container-title:Dermatol Ther (Heidelb)

Author:

Asahina Akihiko^ORCID,Okubo Yukari^ORCID,Morita Akimichi^ORCID,Tada Yayoi^ORCID,Igarashi Atsuyuki^ORCID,Langley Richard G.^ORCID,Deherder Delphine^ORCID,Matano Mizuho^ORCID,Vanvoorden Veerle^ORCID,Wang Maggie^ORCID,Ohtsuki Mamitaro^ORCID,Nakagawa Hidemi^ORCID

Funder

UCB Pharma

Publisher

Springer Science and Business Media LLC

Subject

Dermatology

Link

https://link.springer.com/content/pdf/10.1007/s13555-022-00883-y.pdf

Reference44 articles.

1. Boehncke W-H, Schön MP. Psoriasis. Lancet. 2015;386(9997):983–94.

2. Bhosle MJ, Kulkarni A, Feldman SR, Balkrishnan R. Quality of life in patients with psoriasis. Health Qual Life Outcomes. 2006;4:35.

3. Kimball AB, Jacobson C, Weiss S, Vreeland MG, Wu Y. The psychosocial burden of psoriasis. Am J Clin Dermatol. 2005;6(6):383–92.